Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial

Archives of General Psychiatry

Volumn 63, Issue 10, 2006, Pages 1158-1165

  Davidson, Jonathan ^a   Baldwin, David ^b   Stein, Dan J ^c   Kuper, Enrique ^d   Benattia, Isma ^e   Ahmed, Saeed ^e   Pedersen, Ron ^e   Musgnung, Jeff ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Centro de Stress Traumático   (Argentina)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; NAUSEA; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOMNOLENCE; TREMOR; VOMITING; XEROSTOMIA;

ADULT; AMBULATORY CARE; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DIZZINESS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; LONGITUDINAL STUDIES; MALE; NAUSEA; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 33749362591     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.10.1158     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
2. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048-1060.
3. Brunello N, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G, Shalev AY, Zohar J. Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology. 2001;43:150-162.
4. Asnis GM, Kohn SR, Henderson M, Brown NL. SSRIs versus non-SSRIs in posttraumatic stress disorder: an update with recommendations. Drugs. 2004;64:383-404.
5. Southwick SM, Bremner JD, Rasmusson A, Morgan CA III, Arnsten A, Charney DS. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;46:1192-1204.
6. Kimble M, Kaufman M. Clinical correlates of neurological change in posttraumatic stress disorder: an overview of critical systems. Psychiatr Clin North Am. 2004;27:49-65.
7. McFarlane AC, Yehuda R, Clark CR. Biologic models of traumatic memories and post-traumatic stress disorder: the role of neural networks. Psychiatr Clin North Am. 2002;25:253-270.
8. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
9. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283:3082-3088.
10. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, Emilien G. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19:387-396.
11. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebocontrolled study. Br J Psychiatry. 2005;187:352-359.
12. Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T, Mellman TA, Pontius E, Rosenthal M, Tucker P. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl). 1995;122:386-389.
13. Katz RJ, Lott MH, Arbus P, Crocq L, Herlobsen P, Lingjaerde O, Lopez G, Loughrey GC, MacFarlane DJ, McIvor R. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety. 1994;1:169-174.
14. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006;26:259-267.
15. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson WM, Rausch J, Farfel GM. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry. 2001;62:325-331.
16. The Post-Traumatic Stress Disorder Algorithm. International Psychopharmacology Algorithm Project (IPAP). 2005. http://www.ipap.org. Accessed on December 8, 2005.
17. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8:75-90.
18. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:860-868.
19. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004;65:1696-1707.
20. Guy W. 028 CGI Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Bethesda, Md: US Dept of Health, Education and Welfare, National Institute of Mental Health; 1976:217-222.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. Connor KM, Davidson JR. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety. 2003;18:76-82.
23. Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder? J Clin Psychopharmacol. 1990;10:3-11.
24. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321-326.
25. Sheehan DV. The Anxiety Disease. New York, NY: Charles Scribners Sons; 1983.
26. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect [erratum in: BMJ. 1995;310:1056]. BMJ. 1995;310:452-454.
27. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000;283:1837-1844.
28. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58:485-492.
29. Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry. 2001;158:1982-1988.
30. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63:199-206.
31. Hunsley MS, Palmiter RD. Norepinephrine-deficient mice exhibit normal sleepwake states but have shorter sleep latency after mild stress and low doses of amphetamine. Sleep. 2003;26:521-526.
32. Hunsley MS, Palmiter RD. Altered sleep latency and arousal regulation in mice lacking norepinephrine. Pharmacol Biochem Behav. 2004;78:765-773.
33. Davidson J, Watkins L, Owens M, Krulewicz S, Connor K, Carpenter D, Krishnan R, Nemeroff C. Effects of paroxetine and venlafaxine XR on heart rate variability in depression. J Clin Psychopharmacol. 2005;25:480-484.
34. Davidson JRT, Farfel GM. Effect sizes of rating scales in two multicenter trials of sertraline and placebo in posttraumatic stress disorder [poster]. Presented at: 12th Annual Meeting of the European College of Neuropsychopharmacology; September 21, 1999; London, England.
35. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840-1847.
36. Allgulander C, Hirschfeld RM, Nutt DJ. Long-term treatment strategies in anxiety disorders. Psychopharmacol Bull. 2002;36:79-92.
37. Liebowitz M, Davidson J, Blanco C, Tummala R, Jiang Q. Pooled analysis of response and remission rates with venlafaxine ER in social anxiety disorder [poster]. Presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 11-16, 2005; Waikoloa, Hawaii.